Back

Hemodynamic effects of vericiguat in symptomaticHFrEF patients: insights from right heart catheterization study

1 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Optimisation of heart failure treatment Haemodynamics of Heart Failure ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hideaki Suzuki

Tohoku University Hospital, Sendai (Japan)

8 More presentations in this session

Presentation thumbnail
Up-titration of Guideline Directed Medical Therapy (GDMT) and the occurrence of side effects in Heart Failure with reduced Ejection Fraction (HFrEF)
Doctor N. Panagiotides (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Visit-to-visit changes in heart rate in heart failure: a pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials
Doctor H. Lu (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Use and associations with mortality/morbidity of guideline-directed medical therapy use in heart failure with improved ejection fraction: a PS-matched analysis from the swedish heart failure registry
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction
Doctor X. Wang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Survival benefit of guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis
Doctor E. Tan (Singapore, SG)
Abstract Slides Video

Access the full session

Session thumbnail
Optimisation of heart failure treatment

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
The hemodynamic effect of vericiguat during exercise right heart catheterization in patients with HFrEF
thumbnail
Congress Presentation
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF)
thumbnail
Congress Presentation
Role of Vericiguat on clinical, echocardiographic and comprehensive geriatric assessment parameters in elderly patients with worsening Heart Failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources